background
hepat
b
viru
hbv
infect
major
health
concern
two
billion
individu
current
infect
worldwid
limit
effect
exist
vaccin
drug
develop
novel
antivir
strategi
urgent
need
heat
stress
cognat
atpbind
protein
heat
stress
protein
famili
found
requir
hbv
dna
replic
report
first
time
combin
sirna
target
viral
gene
highli
effect
suppress
ongo
hbv
express
replic
method
construct
two
plasmid
express
short
hairpin
rna
shrna
target
surfac
open
read
frame
hbv
hbv
one
plasmid
express
shrna
target
use
egfpspecif
sirna
plasmid
siegfp
previous
describ
first
evalu
genesilenc
efficaci
shrna
use
enhanc
green
fluoresc
protein
egfp
report
system
flow
cytometri
cell
antivir
potenc
hbvspecif
sirna
sihbv
combin
cell
investig
moreov
type
ifn
induct
measur
quantit
realtim
pcr
elisa
result
cotransfect
either
egfp
plasmid
produc
reduct
egfp
signal
rel
control
combin
rnai
effect
specif
inhibit
hbv
protein
mrna
hbv
dna
result
log
reduct
hbv
load
cell
cultur
supernat
combin
sirna
potent
sihbv
use
separ
approach
enhanc
potenc
suppress
ongo
viral
gene
express
replic
cell
forestal
escap
mutant
hbv
antivir
synergi
sihbv
use
combin
produc
cytotox
induc
product
transfect
cell
conclus
combin
rnai
sequencespecif
effect
wildtyp
mutant
drugresist
hbv
strain
without
trigger
interferon
respons
produc
side
effect
find
indic
combin
rnai
tremend
promis
develop
innov
therapi
viral
infect
million
billion
peopl
world
expos
hepat
b
viru
hbv
chronic
infect
seriou
risk
develop
liver
failur
cirrhosi
hepatocellular
carcinoma
hcc
resid
asiapacif
region
particularli
asian
endem
area
china
year
hbvrelat
death
occur
worldwid
approv
therapi
chronic
hepat
b
includ
interferon
ifn
alfa
nucleo
ide
analogu
rare
elimin
viru
hbv
persist
establish
hbv
coval
close
circular
dna
ccc
dna
hepatocyt
nuclear
transcript
templat
continu
initi
new
hbv
replic
cycl
even
serolog
clearanc
longterm
treatment
case
bear
risk
advers
sideeffect
mutant
drugresist
hbv
strain
therefor
combin
strategi
treat
hbv
differ
angl
urgent
need
infect
hepatocyt
hbv
produc
four
major
class
messeng
rna
mrna
kb
pregenom
rna
reversetranscrib
new
hbv
genom
serv
mrna
translat
viral
core
polymeras
protein
minim
longer
rna
encod
secretori
hepat
b
e
antigen
hbeag
rna
kb
serv
mrna
viral
envelop
protein
l
kb
rna
hbv
x
protein
translat
addit
file
figur
rna
interfer
rnai
sequencespecif
posttranscript
genesilenc
molecular
mechan
first
discov
caenorhabd
elegan
rnai
process
initi
rnase
iii
enzym
known
dicer
process
dsrna
nt
small
interf
rna
sirna
subsequ
sirna
unwound
one
strand
preferenti
load
rnainduc
silenc
complex
risc
load
singlestrand
rna
call
antisens
guid
strand
directli
target
complementari
mrna
cleavag
transcript
repress
degrad
strandth
passengerb
degrad
rnai
induc
via
synthet
sirna
dna
vector
intracellular
express
short
hairpin
rna
shrna
rnaibas
gene
silenc
approach
demonstr
human
ongo
clinic
trial
hold
promis
treat
fatal
disord
provid
altern
tradit
small
molecul
therapi
mani
studi
report
highli
effect
rnaimedi
silenc
human
immunodefici
viru
type
hbv
hepat
c
viru
hcv
hepat
e
viru
influenza
viru
sarscov
ebola
filovirus
cell
cultur
vivo
addit
sirna
found
potent
sequencedepend
induct
mammalian
innat
immun
respons
also
report
possess
bifunct
antivir
molecul
induc
product
type
ifn
liver
target
hbv
inhibit
viral
replic
howev
technic
challeng
remain
deliv
sirna
specif
target
gene
therapeut
accept
way
avoid
advers
side
effect
hbv
strain
reli
heavili
host
cell
machineri
complet
life
cycl
number
host
protein
found
crucial
hbv
hcv
replic
atpbind
protein
famili
host
protein
found
requir
revers
transcript
process
hbv
dna
replic
host
protein
also
target
exampl
sirna
direct
diacylglycerol
acyltransferas
host
gene
product
pololik
kinas
reduc
hcv
product
notabl
nakagawa
et
al
liu
et
al
demonstr
downregul
sirna
significantli
inhibit
hbv
hcv
product
cytotox
cellular
prolifer
apoptosi
current
focu
sever
laboratori
use
mirna
shrna
express
method
target
one
viral
transcript
chronic
hepat
contribut
significantli
hepatocellular
carcinoma
pathogenesi
stimul
interest
new
hbv
therapi
reduc
diseas
burden
previous
show
sequencespecif
inhibit
rnai
hbvhcvfmdv
egfp
vitro
vivo
recent
report
japanes
enceph
viru
infect
cell
presuppos
associ
lipid
raft
hbv
demonstr
promot
tumor
cell
invas
mechan
involv
upregul
heat
shock
protein
far
report
use
sihbv
endogen
target
combin
treat
hbv
demonstr
sihbv
combin
cell
innov
effect
approach
treat
hbv
without
trigger
innat
immun
respons
antivir
synergi
produc
cytotox
affect
cell
viabil
prolifer
sirna
target
conserv
region
hbv
genom
gener
intracellular
dicer
enzym
depict
addit
file
figur
identifi
effect
inhibitori
efficaci
sirna
dna
cassett
region
insert
end
enhanc
green
fluoresc
protein
egfp
gene
construct
report
plasmid
addit
file
figur
report
plasmid
transfect
cell
either
homolog
sirna
heterolog
sirnasth
number
egfpexpress
cell
examin
fluoresc
microscop
h
transfect
verif
rnaimedi
mechan
found
number
cell
visibl
light
compar
cell
transfect
homolog
sirna
rel
cell
transfect
heterolog
sirna
nontransfect
cell
indic
siegfp
vitiat
cellular
growth
surviv
green
fluoresc
light
put
action
could
seen
comparison
group
express
egfp
decreas
markedli
siegfp
group
indic
addit
impact
posttranscript
translat
siegfp
exercis
specif
genesilenc
effect
egfp
result
cessat
egfp
express
figur
b
addit
file
figur
express
egfp
determin
flow
cytometri
conclus
reach
make
comparison
differ
group
figur
addit
file
figur
statist
signific
differ
exist
siegfp
group
control
p
confirm
western
blot
assess
siegfp
inhibit
express
egfp
fusion
protein
produc
result
data
shown
result
demonstr
shrna
gener
sirnaexpress
plasmid
effici
process
intracellular
dicer
enzym
turn
correspond
sirna
rnai
target
gene
figur
cotransfect
either
report
plasmid
produc
reduct
egfp
signal
rel
control
fluorescenceactiv
cell
sort
demonstr
level
inhibit
mediat
sirna
similar
among
differ
experi
group
significantli
higher
control
group
cotransfect
heterolog
sirna
without
sirna
detect
inhibitori
effect
cell
collect
h
transfect
inhibitori
potenc
sirna
assess
quantit
realtim
pcr
revers
transcriptionpcr
rtpcr
assay
level
target
rna
significantli
reduc
cell
transfect
homolog
sirna
specif
amplif
rtpcr
product
confirm
meltcurv
analysi
data
shown
inhibit
egfp
mrna
express
also
demonstr
rtpcr
analysi
correct
transcript
egfp
confirm
sequenc
rtpcr
product
result
suggest
sirna
gener
intracellular
transcript
could
effect
specif
inhibit
express
hbv
transfect
cell
synergist
inhibit
hbv
protein
express
sihbv
combin
determin
knockdown
efficaci
shrna
express
cassett
target
hbv
use
alon
combin
hairpin
express
cassett
target
endogen
amount
hbsag
hbeag
cell
cultur
supernat
determin
use
elisa
differ
time
point
transfect
depict
figur
c
independ
significantli
inhibit
hbsag
hbeag
h
transfect
hbsag
reduc
hbeag
decreas
compar
heterolog
sirna
control
p
shown
figur
express
abrog
compar
control
result
indic
combin
sirna
potent
sihbv
use
separ
specif
inhibit
hbv
mrna
sihbv
combin
depict
figur
could
effect
specif
inhibit
express
hbv
gene
h
transfect
reduct
hbv
mrna
mean
fluoresc
intens
control
sirna
taken
adopt
control
data
repres
three
independ
experi
perform
triplic
signific
differ
compar
heterolog
sirna
control
student
ttest
p
mrna
express
grew
markedli
indic
combin
sirna
potent
use
individu
result
show
combin
rnai
effect
specif
inhibit
express
hbv
mrna
specif
inhibit
hbv
dna
sihbv
combin
depict
figur
compar
control
hbv
dna
decreas
distinctli
cell
cultur
supernat
h
transfect
plasmid
respect
inhibitori
effect
notic
h
transfect
hbv
dna
copi
treat
cell
found
reduc
log
log
log
respect
h
transfect
combin
produc
log
decreas
hbv
load
cell
cultur
supernat
control
show
signific
reduct
heterolog
sirna
time
point
thu
sirna
hbv
genom
target
endogen
gene
target
combin
effect
specif
result
overal
reduct
viru
load
indic
combin
sirna
potent
sihbv
use
separ
highlyconserv
essenti
stress
protein
therefor
next
investig
whether
genesilenc
host
protein
affect
cell
viabil
consequ
viral
product
mtt
assay
measur
determin
sirnamedi
silenc
signific
effect
cellular
prolifer
cytotox
gapdh
western
blot
use
intern
control
verifi
equival
number
cell
use
assay
result
indic
sirnamedi
gene
silenc
affect
cell
viabil
effect
sirna
cell
investig
whether
ifn
pathway
induct
could
stimul
sirna
transfect
cell
report
earlier
studi
result
show
positivecontrol
poli
c
caus
intens
secret
cell
sirna
induc
product
transfect
cell
figur
b
mrna
concentr
detect
cell
measur
elisa
rtpcr
figur
combin
receptor
respons
gener
poli
c
ifn
activ
downstream
signal
pathway
induc
releas
type
ifn
seen
figur
poli
c
induc
strong
ifn
respons
cell
result
massiv
express
express
comparison
cell
transfect
plasmid
reveal
impact
siegfp
product
type
ifn
transfect
cell
neglig
immunostimul
taken
togeth
show
poli
c
could
induc
ifn
respons
cell
indic
express
receptor
cell
littl
none
found
sirna
test
induc
innat
ifn
respons
wherea
poli
c
control
good
stimul
studi
show
first
time
combin
sirna
target
gene
hbv
specif
highli
effect
suppress
ongo
viral
gene
express
replic
cell
forestal
escap
mutant
hbv
combin
sirna
potent
sihbv
use
separ
without
trigger
ifn
respons
produc
side
effect
agreement
research
liu
et
al
work
demonstr
antivir
synergi
sihbv
use
combin
produc
cytotox
affect
cell
viabil
recent
modular
trimer
pol
ii
express
cassett
compris
mirna
shuttl
use
success
gener
multiplex
antihbv
rnai
activ
construct
plasmid
sihbv
employ
hbv
gene
target
endogen
gene
target
combin
eli
et
al
report
construct
mir
express
plasmid
gener
cassett
use
modul
combin
trimer
express
pol
ii
promot
plasmid
construct
combin
approach
adopt
markedli
differ
eli
et
al
interestingli
studi
produc
result
molecular
chaperon
initi
discov
mediat
cellular
heat
shock
respons
subsequ
studi
demonstr
promiscu
function
protein
includ
relat
cancerand
virusassoci
pathogenesi
heat
stress
protein
famili
compos
highli
conserv
protein
includ
heat
shock
protein
wellcharacter
multifunct
molecular
chaperon
involv
regul
signal
transduct
transcript
activ
oncogen
protein
stabil
neovascularizationpathogen
element
relev
viral
cancer
pathogenesi
despit
function
primarili
cytoplasm
chaperon
famili
member
found
surfac
variou
cell
type
tumor
cell
neural
stem
cell
spermatogen
cell
epiderm
cell
arteri
smooth
muscl
cell
monocyt
bcell
hsp
act
viru
receptor
cell
surfac
describ
viral
infect
eg
rotavirus
human
lymphotrop
viru
type
coxsackieviru
denv
host
protein
play
critic
role
variou
stage
viru
life
cycl
entri
replic
assembl
egress
viru
particl
found
play
role
life
cycl
varieti
rna
dna
virus
inhibitor
mrnaprotein
express
could
inhibit
hbvhcv
replic
effici
medic
inhibit
express
effect
suppress
infect
wildtyp
viral
strain
effect
viral
strain
resist
lamivudin
suchlik
medic
thu
effect
obviat
hbv
resist
drug
unlik
target
viral
gene
enzym
sirna
specif
host
gene
would
effect
wildtyp
mutant
drugresist
hbv
strain
suppress
mrna
express
host
cell
markedli
suppress
hbv
replic
drug
target
activ
wildtyp
hbv
simultan
suppress
replic
viral
strain
resist
lamivudin
entecavir
telbivudin
kindr
drug
hbv
rna
share
common
sequenc
may
target
singl
sirna
replic
viru
suscept
rnaimedi
inhibit
unlik
hcv
hbv
genom
prone
mutat
escap
silenc
antivir
shrna
primarili
hbv
highli
compact
genom
overlap
read
frame
addit
file
figur
factor
might
explain
least
part
two
hbvspecif
sirna
highest
efficaci
two
plasmid
construct
target
conserv
region
sequenc
hbv
genom
subtyp
ayw
ident
viru
previous
report
genbank
access
number
ay
ay
plasmid
hbvspecif
b
figur
specif
inhibit
hbv
gene
sirna
target
viral
gene
combin
cell
inhibit
hbv
mrna
sirna
differ
time
point
cell
transfect
also
heterolog
data
repres
three
independ
experi
perform
triplic
signific
differ
compar
heterolog
sirna
control
student
ttest
p
b
inhibit
hbv
dna
sirna
cell
cultur
supernat
cell
transfect
also
heterolog
data
repres
three
independ
experi
perform
triplic
sirna
sihbv
directli
knock
transcript
hbv
novel
potenti
target
develop
drug
hbv
indirectli
inhibit
hbv
replic
express
virtu
inhibit
host
protein
involv
hbv
infect
target
site
function
mechan
differ
antivir
effect
work
synergi
sirna
directli
target
hbv
gene
liabl
forfeit
inhibitori
efficaci
account
hbv
gene
mutat
select
pressur
target
site
host
protein
remark
stabil
subject
mutat
normal
circumst
term
inhibit
express
hbv
e
protein
use
conjunct
potent
use
isol
respect
importantli
result
show
combin
rnai
markedli
inhibit
hbv
protein
mrna
hbv
dna
result
log
reduct
hbv
load
cell
cultur
supernat
gene
knockout
gener
abnorm
mice
prove
safeti
inhibit
therefor
combin
sirna
exercis
effect
make
flaw
thu
inhibit
wildtyp
hbv
also
inhibit
infecti
mutant
strain
well
elicit
signific
inhibit
hbv
suggest
sirna
mediat
signific
reduct
specif
target
mrna
gener
downregul
result
activ
dsrnaactiv
protein
kinas
r
pkr
could
induc
inhibit
protein
translat
nonsequ
specif
manner
well
known
rnai
act
natur
antivir
defens
mechan
plant
especi
rna
virus
mammalian
cell
origin
presum
unlik
inher
possess
activ
rnasilenc
machineri
primarili
induc
nonspecif
interferonmedi
antivir
respons
mediat
dsrna
especi
viral
long
dsrna
sirna
sequenc
test
show
vigor
ifna
respons
reportedli
mani
case
transfect
sirna
even
sirna
result
ifnmedi
activ
jakstat
pathway
global
upregul
ifnstimul
gene
isg
mediat
pkr
tolllik
receptor
tlr
therefor
may
innat
immun
system
recogn
immunostimulatori
rna
motif
within
singlestrand
rna
ssrna
doublestrand
rna
dsrna
via
work
requir
defin
core
rna
motif
underli
immun
recognit
sirna
shown
restrict
cell
innat
immun
system
previou
studi
report
activ
ifn
pathway
induct
respons
transcrib
sirna
cell
induct
ifn
effect
cellular
signal
pathway
indic
sirna
broad
effect
beyond
select
silenc
homolog
target
gene
introduc
cell
present
studi
indic
vectorbas
sirna
without
sequenc
ugugu
lower
ratio
ug
content
minim
side
effect
innat
immun
system
still
studi
report
differ
result
indic
mechan
induc
innat
ifn
respons
reduc
length
sequenc
depend
compel
conjectur
possibl
role
rna
structur
might
play
regard
whether
sirna
induc
innat
immun
respons
mammalian
cell
differ
studi
produc
differ
result
present
clear
understand
mechan
determin
genesilenc
effici
given
sirna
virus
evolv
mechan
suppress
escap
rnai
strategi
aim
provid
rapid
effici
protect
hbv
surmount
major
challengethat
acut
infect
viru
presum
sirna
elicit
antivir
respons
cell
within
h
promis
develop
emerg
rnai
vaccin
prevent
viru
diseas
especi
capabl
produc
prompt
prophylact
therapeut
effect
hbv
addit
differ
effici
gene
silenc
due
differ
structur
sirna
target
suggest
layer
complex
address
includ
extent
conserv
rnai
machineri
activ
mani
differ
mammalian
cell
type
still
mani
hurdl
overcom
rnai
use
treat
chronic
hbv
particularli
relat
appropri
deliveri
rnai
molecul
ii
continu
presenc
cccdna
hepatocyt
nucleu
provid
constant
sourc
viral
mrna
pregenom
howev
find
suggest
combin
rnai
worth
pursu
develop
new
approach
treat
cure
million
peopl
worldwid
live
chronic
hbv
infect
studi
conduct
mammal
order
obtain
unanticip
result
regard
aforement
issu
therapeut
applic
combin
rnai
system
term
viral
clearanc
result
highlight
interest
combin
therapi
approach
capabl
reduc
drug
toxic
prevent
antivir
compound
drug
resist
thu
minim
chanc
viral
escap
innov
combin
rnai
approach
treat
hbv
fundament
distinct
inhibit
viral
express
well
inhibit
viral
replic
weak
host
immun
respons
associ
chronic
hbv
infect
make
virtual
imposs
achiev
sustain
complet
viral
clearanc
even
longterm
suppress
hbv
dna
replic
lamivudin
telbivudin
presum
therapi
fail
reduc
high
viral
antigenemia
believ
mitig
cell
respons
chronic
infect
patient
therebi
help
hbv
avoid
immun
clearanc
contrast
reduc
viral
antigen
level
attain
combin
rnaimedi
degrad
viral
rna
transcript
pregenom
rna
precor
hbsag
mrna
may
reliev
neg
effect
chronic
antigen
stimul
cell
respons
facilit
recoveri
immun
respons
sinc
certain
viral
protein
hbeag
report
suppress
innat
immun
respons
inhibit
viral
persist
reduct
viral
protein
synthesi
could
addit
benefit
rnai
mediat
therapi
littl
decad
rnai
discoveri
led
understand
molecular
process
respons
small
rna
biogenesi
function
well
develop
reagent
util
power
rnai
pathway
notwithstand
numer
hurdl
translat
technolog
therapi
import
consider
therapeut
rnai
gene
silenc
approach
rare
remov
transcript
offtarget
silenc
occur
target
organ
cell
type
target
transcript
present
uniqu
challeng
promis
earli
clinic
result
warrant
guard
optim
summari
demonstr
first
time
combin
rnai
specif
highli
effect
suppress
ongo
viral
gene
express
replic
cell
forestal
escap
mutant
hbv
combin
sirna
potent
hbv
sirna
use
separ
without
trigger
interferon
respons
produc
side
effect
approach
markedli
inhibit
hbv
protein
mrna
hbv
dna
result
log
reduct
hbv
load
cell
cultur
supernat
antivir
synergi
sihbv
combin
produc
cytotox
induc
product
transfect
cell
although
approach
prove
effect
therapi
hbv
clinic
applic
remain
test
examin
nonetheless
data
present
justifi
continu
explor
innov
combin
rnai
approach
treat
hbvhcv
hiv
infect
refer
sequenc
conserv
region
hbv
genom
obtain
nation
center
biotechnolog
inform
ncbi
websit
wwwncbinlmnihgov
compar
hbv
nucleotid
nt
blast
gene
region
interest
essenti
life
cycl
viru
rel
conserv
nucleotid
sequenc
diagram
addit
file
figur
hbv
target
sequenc
chosen
region
overlap
viral
rna
accord
paramet
indic
sirna
target
finder
web
site
wwwambioncom
nt
target
sequenc
select
potenti
sirna
target
site
base
gene
target
conserv
region
hbv
genom
origin
cell
stabl
hbv
dnaproduc
cell
line
subtyp
ayw
genbank
access
number
comparison
hbv
genom
sequenc
subtyp
ayw
genbank
access
number
hbv
subtyp
ayr
genbank
access
number
adw
genbank
access
number
adr
genbank
access
number
genom
sequenc
mean
dna
star
softwar
megalign
show
two
sirna
target
hbv
gene
respect
homolog
subtyp
ayw
sequenti
analysi
found
sequenc
homolog
exhibit
two
mutant
nt
ntin
four
subtyp
hbv
genom
sequenc
sequenc
homolog
one
mutant
point
addit
file
figur
addit
file
figur
theori
sirna
target
fewer
mutant
point
hbv
genom
would
exercis
crossinhibitori
effect
variou
subtyp
construct
two
plasmid
express
shrna
target
sequenc
hbv
genbank
sequenc
data
access
number
one
sirnaexpress
plasmid
use
control
egfpspecif
sirna
plasmid
siegfp
previous
describ
method
ident
construct
two
shrnaexpress
plasmid
briefli
mous
promot
chemic
synthes
genbank
sequenc
data
access
number
clone
ndeiecori
site
vector
invitrogen
replac
human
cytomegaloviru
promot
pcmv
gener
parent
vector
invert
repeat
target
genom
hbv
addit
file
figur
subclon
ecorihindiii
site
control
termin
signal
five
thymidin
ts
addit
file
figur
plasmid
contain
invert
repeat
correspond
nt
nt
dna
hbv
plasmid
contain
invert
repeat
correspond
nt
nt
dna
hbv
control
nonspecif
effect
use
shrnaexpress
plasmid
contain
invert
repeat
heterolog
hbv
genom
confirm
sequenc
analysi
provid
report
system
evalu
genesilenc
efficaci
sirna
dna
nt
hbv
obtain
rtpcr
dna
extract
cell
templat
use
primer
sens
antisens
primer
retrotranscript
egfp
mrna
sens
antisens
rtpcr
product
clone
tvector
sequenc
gener
clone
dna
hbv
ecoribamhi
site
clontech
palo
alto
ca
form
fusion
egfp
addit
file
figur
report
plasmid
construct
respect
use
previous
report
method
correct
open
read
frame
confirm
sequenc
retain
fluoresc
properti
fusion
protein
three
human
cell
line
obtain
atcc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
ca
supplement
fetal
calf
serum
invitrogen
unitsml
penicillinstreptomycin
lglutamin
co
cell
addit
maintain
medium
contain
day
transfect
cell
seed
plate
approxim
cell
well
achiev
confluent
cell
monolay
cell
transfect
shrnaexpress
plasmid
cell
transfect
reportertarget
plasmid
either
shrnaexpress
plasmid
combin
use
lipofectamin
invitrogen
accord
protocol
provid
manufactur
transfect
effici
calcul
ratio
number
viabl
transfect
cell
versu
nontransfect
cell
experi
transfect
effici
routin
evalu
effect
inhibitori
efficaci
sirna
express
egfp
cotransfect
cell
identifi
egfp
posit
cell
fluoresc
microscopi
flow
cytometri
becton
dickinson
san
jose
ca
addit
h
incub
cell
observ
express
egfp
olympu
microscop
photograph
use
nikon
video
camera
magnif
exposur
time
cell
subject
fluorescenceactiv
cell
sort
use
previous
describ
method
silenc
effici
quantifi
flow
cytometri
specif
silenc
target
gene
confirm
rtpcr
sequenc
primer
retrotranscript
egfp
mrna
sens
antisens
rtpcr
product
clone
tvector
sequenc
equal
number
cell
transfect
heterolog
sequenc
h
lyse
sd
sampl
buffer
depict
figur
cell
lysat
separ
sdspage
protein
transfer
onto
polyvinyliden
fluorid
pvdf
membran
millipor
use
semidri
electrophoret
transfer
system
biorad
ca
probe
monoclon
antibodi
specif
clone
stressgen
dehydrogenas
gapdh
follow
incub
horseradish
peroxidaselabel
goat
antimous
igg
secondari
antibodi
santa
cruz
biotechnolog
bound
antibodi
detect
enhanc
chemiluminesc
ecl
plu
western
blot
detect
reagent
perkinelm
life
scienc
protein
express
also
examin
flow
cytometri
use
previous
describ
method
detect
hbv
replic
total
rna
extract
cell
cultur
qiagen
rneasi
mini
kit
subject
quantit
realtim
revers
transcriptionpcr
rtpcr
brief
rtpcr
perform
plate
biorad
hercul
ca
reaction
volum
contain
compon
sybr
rtpcr
kit
perfect
real
time
takara
kyoto
japan
reaction
mixtur
contain
sybr
master
mix
forward
primer
revers
primer
respect
rna
sampl
water
cycl
program
consist
min
follow
cycl
primer
retrotranscript
hbv
mrna
sens
antisens
confirm
specif
amplif
meltingcurv
analysi
rtpcr
product
perform
accord
manufactur
protocol
fluoresc
measur
cycl
display
graphic
icycl
iq
realtim
pcr
detect
system
softwar
biorad
hercul
ca
gapdh
use
intern
control
sens
antisens
primer
cycl
program
employ
cycl
paramet
qrtpcr
describ
rel
mrna
level
hbv
quantit
ratio
hbv
gene
product
quantiti
ng
gapdh
rtpcr
product
clone
tvector
sequenc
amount
hepat
b
surfac
antigen
hbsag
e
antigen
hbeag
cell
cultur
supernat
quantifi
use
commerci
elisa
kit
abbott
laboratori
north
chicago
il
assay
perform
triplic
independ
experi
measur
viral
load
hbv
dna
extract
cell
cultur
supernat
use
qiaamp
dna
mini
kit
qiagen
hilden
germani
hbv
dna
level
quantifi
use
roch
diagnost
coba
taqman
meylan
franc
detect
limit
hbv
dna
copiesml
hbv
genotyp
identifi
use
gene
fragment
sequenc
mtt
cell
viabil
assay
describ
previous
briefli
cell
plate
plate
densiti
cellswel
transfect
plasmid
either
individu
combin
nonspecif
control
sirna
transfect
h
h
cell
prolifer
cellular
toxic
analyz
mtt
assay
mtt
assay
medium
well
replac
medium
contain
mtt
h
incub
mttcontain
medium
remov
dmso
ad
well
plate
agit
min
dark
dissolv
mttformazan
crystal
sampl
absorb
measur
nm
experi
perform
triplic
result
present
